Mechanism of Action: HER2/Neu/cerbB2 Antagonists
✉ Email this page to a colleague
Drugs with Mechanism of Action: HER2/Neu/cerbB2 Antagonists
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | HERNEXEOS | zongertinib | TABLET;ORAL | 219042-001 | Aug 8, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Boehringer Ingelheim | HERNEXEOS | zongertinib | TABLET;ORAL | 219042-001 | Aug 8, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Boehringer Ingelheim | HERNEXEOS | zongertinib | TABLET;ORAL | 219042-001 | Aug 8, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
